The study was recently presented at the American Association of Hip and Knee Surgeons 25th Annual Meeting in Dallas. It included a retrospective evaluation of more than 2,600 patients divided into two cohorts.
The first cohort consisted of patients who had previously been treated with an aggressive chemoprophylaxis protocol (using enoxaparin, rivaroxaban and warfarin). The second cohort consisted of patients either undergoing treatment with prophylactic synchronized mobile compression and aspirin or aggressive chemoprophylaxis.
Ultimately, the researchers found patients in the second cohort experienced lower rates of VTE, fewer adverse events, readmissions, infections and bleeding-related complications than the group treated with anticoagulation.
Additionally, hospital costs were significantly lower among the patients in the synchronized mobile compression and aspirin group than the first cohort.
More articles on blood clots:
How to prevent blood clots: 10 stories, studies, tips and tricks from this year
Peripherally inserted central catheters come with risk of lower-limb blood clots, study finds
Dr. Peter Pronovost: Dangerous blood clots tend to fly ‘under the radar’ in hospitals
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.